Therapeutic advantages of pegylation of interferon alpha in chronic hepatitis C;Ventajas terapéuticas de la pegilación del interferón alfa en la hepatitis crónica C

Revista Espanola de Enfermedades Digestivas

Volumn 95, Issue 8, 2003, Pages 568-574

  Medina, J ^a   Garcia Buey L ^a   Moreno Monteagudo, J A ^a   Trapero Marugan M ^a   Moreno Otero, Ricardo ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Antiviral therapy; Combined therapy; Hepatitis C; Interferon; Pegylated interferon; Ribavirin

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; RIBAVIRIN;

CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; HEPATITIS C; HUMAN; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TREATMENT FAILURE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CLINICAL TRIALS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 0042831216     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Baillargeon MW, Sonnet P. Lipase modified for solubility in organic solvents. Ann N Y Acad Sci 1988; 542: 244-9.
2. Cao SG, Zhao Q, Ding Z, Ma L, Yu T, Wang J, et al. Chemical modification of enzyme molecules to improve their characteristics. Ann N Y Acad Sci 1990; 613: 460-7.
3. Chen RH, Abuchowski A, Van-Es T, Palczuk N, Davis F. Properties of two urate oxidases modified by the covalent attachment of poly(ethylene glycol). Biochim Biophys Acta 1981; 660: 293-8.
4. Hadley KB, Sato P. Catalytic activity of administered gulonolactone oxidase polyethylene glycol conjugates. Enzyme 1989; 42: 225-34.
5. Suzuki T, Kanbara N, Tomono T, Hayashi N, Shinohara I. Physicochemical and biological properties of poly(ethylene glycol)-coupled immunoglobulin G. Biochim Biophys Acta 1984; 788: 248-55.
6. Ho DH, Brown N, Yen A, Holmes R, Keating M, Abuchowski A, et al. Clinical pharmacology of polyethylene glycol-L-asparaginase. Drug Metab Dispos 1986; 14: 349-52.
7. Knauf MJ, Bell D, Hirtzer P, Luo Z, Young J, Katre N. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem 1988; 263: 15064-70.
8. Mast AE, Salvesen G, Brucato F, Schnebli H, Pizzo S. Polyethylene glycol modification of serpins improves therapeutic potential. Biol Chem Hoppe Seyler 1990; 371: 101-9.
9. Abuchowski A, Kazo G, Verhoest C, Van-Es T, Kafkewitz D, Nucci M, et al. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethyleneglycol-asparaginase conjugates. Cancer Biochem Biophys 1984; 7: 175-86.
10. Davis S, Abuchowski A, Park Y, Davis. F. Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. Clin Exp Immunol 1981; 46: 649-52.
11. Nucci ML, Olejarczyk J, Abuchowski A. Immunogenicity of polyethylene glycol-modified superoxide dismutase and catalase. J Free Radic Biol Med 1986; 2: 321-5.
12. Tsuji J, Hirose K, Kasahara E, Naitoh M, Yamamoto I. Studies on anti-genicity of the polyethylene glycol (PEG)-modified uricase. Int J Immunopharmacol 1985; 7: 725-30.
13. Yokoyama M, Miyauchi M, Yamada N, Okano T, Sakurai Y, Kataoka K, et al. Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly (ethylene glycol)-poly (aspartic acid) block copolymer. Cancer Res 1990; 15: 1693-700.
14. Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly (ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci 1994; 83: 601-6.
15. Kita Y, Rohde M, Arakawa T, Fagin K, Fish E, Banerjee K. Characterization of a polyethylene glycol conjugate of recombinant human interferon-gamma. Drug Des Deliv 1990; 6: 157-67.
16. Lam NP, Neumann A, Gretch D, Whiley T, Perelson A, Layden T. Dose-dependent acute clearance of hepatitis C genotype 1 with interferon alfa. Hepatology 1997; 26: 226-31.
17. Monkarsh SP, Ma Y, Aglione A, Bailon P, Ciolek D, DeBarbieri B, et al. Positional isomers of monopegylated interferon alpha-2a: isolation, characterization and biological activity. Analytical Biochem 1997; 247: 434-40.
18. Wang YS, Youngster S, Bausch J. Indentication of the major positional isomer of pegylated interferon alpha-2b. Biochemistry 2000; 39: 10634-40.
19. Algranati NE, S Sy, Modi M. A branched methoxy 40 KDA polyethylene glycol (PEG) moiety optimizes the pharmacokinetics of peginterferon alpha-2A and may explain its enchanced efficacy in chronic hepatitis C. Hepatology 1999; 30: 190.
20. Xu ZX, Hoffman J, Patel I, Joubert P. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon alfa-2a (IFN alfa-2a) to healthy subjects. Hepatology 1998; 28: 702A.
21. Glue P, Fang J, Sabo R, Rouzier-Panis R, Raffanel C, Gupta S, et al. PEG-interferon alpha-2b: Pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data [abstract]. Hepatology 1999; 30: 189A.
22. Merrit JA, Borden E, Ball L. Measurement of 2′5′-oligoadenylate synthetase in patients receiving interferon alpha. J Interferon Res 1985; 5: 191-8.
23. Modi MW, Fulton J, Buckmann D, Wright T, Moore D. Clearance of pegylated (40KDa) interferon alfa-2a(Pegasys) is primarily hepatic. Hepatology 2000; 32: 371A.
24. Glue P, Fang J, Rouzier-Panis R. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clinical Pharmacology & Therapeutics. 2000; 68: 556-67.
25. Lindsay KL, Trepo C, Heintges T, Shiffman M, Gordon S, Hoefs J, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
26. Heathcote EJ, Pockros P, Fried M, Bain M, DePamphilis J. The pharmacokinetics of pegylated-40K interferon alfa-2a in chronic hepatitis C patients with cirrhosis. Gastroenterology 1999; 116: A735.
27. Schalm SW FG, Brouwer JT. Therapy of hepatitis C: Patients with cirrhosis. Hepatology 1997; 26: 128S-132S.
28. Martin NE, Modi M, Reddy K. Characterization of Pegylated (40kDa) interferon alfa-2a (PEGASYS) in the elderly. Hepatology 2000; 32: 348A.
29. Martin P, Mitra S, Farrington K, Martin N, Modi M. Pegylated (40kDa) interferon alfa-2a (PEGASYS) is unaffected by renal impairment. Hepatology 2000; 32: 370A.
30. Lamb MW, Marks I, Wynohradnyk L, et al. Peginterferon alfa-2a (40 KD) (PEGASYS) can be administered safely in patients with end-stage renal disease. In: American Association for the Study of Liver Disease, 52th Annual Meeting; Dallas, EEUU; 2001.
31. Zeuzem S, Feinman S, Rasenack J, Heathcote E, Lai M, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72.
32. Reddy KR, Wright T, Pockros P, Shiffman M, Everson G, Reindollar R, et al. Efficacy and safety of pegylated (40-kd) interferon [alpha]-2a compared with interferon [alpha]-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-8.
33. Heathcote EJ, Shiffman M, Cooksley W, Dusheiko G, Lee S, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-80.
34. Manns MP, McHutchison J, Gordon S, Rustgi V, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
35. Fried MW, Shiffman M, Reddy R, Smith C, Marinos G, Goncales F, et al. Peg interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med 2002; 347: 975-82.
36. Cornberg M, Hadem J, Bastuerk M. Early HCV RNA decline during treatment with peginterferon alfa-2b plus ribavirin or conventional interferon alfa-2b plus ribavirin: analysis of 80 patients treated at a single center. Hepatologgy 2001; 34: 217A.
37. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-44.
38. Hadziyannis SJ, Cheinquer H, Morgan T, Diago M, Jensen D, Sette H. Peginterferon alfa-2a (40kD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomised, double-blind multicentre study examining effect of duration of treatment and RBV dose. J Hepatol 2002; 36: 3.
39. NIH. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C. Hepatology 2002; 36: S3-S20.
40. Medina J, García-Buey L, Moreno-Monteagudo J, Trapero-Marugán M, Moreno-Otero R. Combined antiviral options for the treatment of chronic hepatitis C. Antiviral Res (In press).
41. McHutchison JG, Patel K. Future therapy of hepatitis C. Hepatology 2002; 36: S245-52.